July 16--St. Jude Medical Inc. said its second-quarter profit more than doubled as sales rose solidly for heart-related devices.
The Little Canada-based company raised its outlook for the rest of the year based in part on the performance.
St. Jude said its net profit was $270 million, or 93 cents a share, up from $115 million, or 40 cents a share, a year ago.
Adjusted earnings, which exclude one-time charges and credits, amounted to $295 million, or $1.02 a share, compared to $275 million, or 96 cents a share, a year ago.
Sales increased 3 percent to $1.45 billion.
Sales of cardiac rhythm management products, St. Jude's largest product category, were $733 million, up 2 percent. Sales of atrial fibrillation products amounted to $257 million, an 8 percent increase.
During the period, St. Jude closed on its $375 million acquisition of the remaining portion of Atlanta-based CardioMEMS Inc. it didn't already own. CardioMEMS makes an implantable heart failure monitoring device.
Earlier this week, St. Jude announced a $200 million dollar acquisition of NeuroTherm Inc., a maker of chronic pain management therapies. The acquisition is expected to boost St. Jude's chronic pain management business. Sales of its existing neuromodulation products dipped 1 percent in the latest quarter to $107 million.
In raising its guidance, St. Jude said it now expects full-year sales to be about $30 million higher, in the range of $5.64 billion to $5.76 billion. It lifted its earnings per share forecast by a penny to a range of $3.96 to $4.01.
For the first six months, St. Jude reported sales of $2.8 billion, up 2.6 percent. Net earnings were $519 million, up from $338 million. Adjusted earnings were $573 million, or $1.98 a share, up from $538 million, or $1.87 a share.
Patrick Kennedy -- 612-673-7926
(c)2014 the Star Tribune (Minneapolis)
Visit the Star Tribune (Minneapolis) at www.startribune.com
Distributed by MCT Information Services